Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transferring robotic expertise from multi-port to single-port partial nephrectomy: A comparative analysis of perioperative outcomes and learning curves.

BJUI compass·2026

Same author

Preliminary feasibility of SHURUI single-port robot-assisted radical cystectomy with exploratory comparison to a contemporaneous da Vinci Xi single-port cohort.

Minerva urology and nephrology·2026

Same author

Biopsy-to-treatment delay in prostate cancer: Postpandemic impact in a swiss national, multicenter, prospective registry.

Urologic oncology·2026

Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Same author

Omitting biopsy in Prostate Imaging Reporting and Data System 3? The role of Stockholm3 and prostate-specific antigen density findings from a prospective Swiss non-referral cohort.

Prostate international·2026

Same author

Changing Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Oct 21, 2025

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

Swiss germ-cell cancer consensus recommendations.

Jörg Beyer¹, Dominik Berthold², Peter-Karl Bode³

¹Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsklinik der Universität Bern, Universität Bern, Switzerland.

Swiss Medical Weekly

|September 8, 2021

Summary

Germ-cell cancer (GCC) management in Switzerland requires personalized treatment strategies. Swiss experts convened to harmonize concepts and optimize care, balancing overtreatment risks with necessary intensification for adverse prognostic factors.

More Related Videos

Mouse Round Spermatid Injection

Mouse Round Spermatid Injection

Published on: January 26, 2024

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Experiment Videos

Last Updated: Oct 21, 2025

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

Mouse Round Spermatid Injection

Mouse Round Spermatid Injection

Published on: January 26, 2024

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Area of Science:

Oncology
Urology

Background:

Germ-cell cancer (GCC) affects approximately 420 men annually in Switzerland.
Management guidelines exist but many aspects of individualized treatment remain controversial.
Balancing overtreatment to avoid toxicity and treatment intensification for adverse factors is crucial.

Purpose of the Study:

To harmonize management concepts for GCC patients in Switzerland.
To suggest optimal strategies for GCC treatment based on expert consensus.
To address controversial issues in GCC management through expert voting.

Main Methods:

A consensus meeting of Swiss experts was held virtually during the Swiss Oncology and Haematology Congress (SOHC) in 2020.
Expert strategies for GCC management were discussed.
Votes on controversial issues were obtained and presented.

Main Results:

Swiss experts discussed and aimed to harmonize GCC management strategies.
Optimal strategies for individual patient treatment were proposed.
Consensus was reached on several controversial aspects of GCC care.

Conclusions:

Personalized treatment is essential for germ-cell cancer (GCC) patients.
Referral to expert centers or second opinions is strongly recommended.
Harmonized strategies can optimize GCC management and reduce long-term toxicities.